Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AG1295 |
Synonyms | |
Therapy Description |
AG1295 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer cells (PMID: 11468194, PMID: 7954456, PMID: 29143227). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AG1295 | AG-1295|AG 1295 | FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 | AG1295 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer cells (PMID: 11468194, PMID: 7954456, PMID: 29143227). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 I836S | hematologic cancer | no benefit | AG1295 | Preclinical - Cell culture | Actionable | In a preclinical study, AG1295 did not inhibit viability of transformed cells expressing FLT3 I836S in culture (PMID: 28077790). | 28077790 |
FLT3 D835K FLT3 D835L | hematologic cancer | no benefit | AG1295 | Preclinical - Cell culture | Actionable | In a preclinical study, AG1295 did not inhibit viability of transformed cells expressing FLT3 D835L and D835K in culture (PMID: 28077790). | 28077790 |
FLT3 I836T | hematologic cancer | no benefit | AG1295 | Preclinical - Cell culture | Actionable | In a preclinical study, AG1295 did not inhibit viability of transformed cells expressing FLT3 I836T in culture (PMID: 28077790). | 28077790 |
FLT3 I836D FLT3 I836L | hematologic cancer | no benefit | AG1295 | Preclinical - Cell culture | Actionable | In a preclinical study, AG1295 did not inhibit viability of transformed cells expressing FLT3 I836D and I836L in culture (PMID: 28077790). | 28077790 |
FLT3 Q575del | hematologic cancer | sensitive | AG1295 | Preclinical - Cell culture | Actionable | In a preclinical study, AG1295 decreased downstream signaling and proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). | 33914060 |
FLT3 D835A | hematologic cancer | no benefit | AG1295 | Preclinical - Cell culture | Actionable | In a preclinical study, AG1295 did not inhibit viability of transformed cells expressing FLT3 D835A in culture (PMID: 28077790). | 28077790 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|